Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Coronavirus: Gilead...

    Coronavirus: Gilead drug remdesivir raises hope for China trials

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-14T12:42:37+05:30  |  Updated On 14 Feb 2020 7:12 AM GMT
    Coronavirus: Gilead drug remdesivir raises hope for China trials

    A state-run Chinese research institute applied last week fora patent to use Gilead's experimental drug- remdesivir against the new coronavirus.

    Chicago: An experimental Gilead Sciences antiviral drug prevented disease and reduced the severity of symptoms in monkeys infected with Middle East Respiratory Syndrome (MERS), an infection closely related to the fast-spreading coronavirus that originated in China, a study published on Thursday found.

    The results, reported in Proceedings of the National Academy of Sciences, raise hope that the drug, remdesivir, currently in clinical trials in China, might be effective against the new virus that has infected some 60,000 people globally and killed more than 1,300, mostly in China.

    However, remdesivir had previously been shown to be protective in monkeys infected with the Ebola virus, but that did not translate to humans.

    "It wasn't successful in Ebola, but there is some indication that it might be successful in the coronaviruses," Dr Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), said in a recent interview.

    NIAID scientists tested remdesivir in monkeys 24 hours prior to infection with MERS and in other monkeys 12 hours after infection - the time frame in monkeys when the virus is most active. They were compared with untreated monkeys in a control group. After six days, all of the untreated animals got sick.

    In the monkeys treated prior to infection, the drug appeared to prevent disease. Animals in this group showed no sign of infection, had significantly lower levels of virus in their lungs and no lung damage.

    Those treated after infection also fared better than the control group. They had less severe disease, their lungs had lower levels of virus and they had less severe lung damage, researchers found.

    Many drugs that succeed in monkeys fail in humans. Nevertheless, the researchers said their findings bolster hopes for the ongoing studies in China and for compassionate use of the drug in severely ill patients.

    The MERS study was supported in part by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.

    A state-run Chinese research institute applied last week fora patent to use Gilead's experimental drug against the new coronavirus.

    https://pubads.g.doubleclick.net/gampad/ads?iu=/21687779244/clinicalkey_video_ad&description_url=[placeholder]&tfcd=0&npa=0&sz=640x480&gdfp_req=1&output=vast&unviewed_position_start=1&env=vp&impl=s&correlator=

    Dr Marie-Paule Kieny, a former World Health Organisation virologist who co-chaired a research forum in Geneva this week, said Chinese researchers will soon start testing the drug on patients, but it could be a few weeks before they know whether it is having any effect.

    Read also: Gilead offers to test Ebola drug remdesivir as new coronavirus treatment in China

    Gilead coronavirus WHO remdesivir ebola 
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X